ESPR - Esperion

-

$undefined

N/A

(N/A)

Esperion NASDAQ:ESPR Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.

Location: 3891 Ranchero Dr Ste 150, Michigan, 48108-2837, US | Website: www.esperion.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

538M

Cash

144.7M

Avg Qtr Burn

-6.44M

Short % of Float

16.53%

Insider Ownership

0.36%

Institutional Own.

66.13%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nexlizet (bempedoic acid and ezetimibe) Details
Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction

Approved

Quarterly sales

Nexletol (bempedoic acid) Details
Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia

Approved

Quarterly sales